Photo by sarahdorweiler from unsplash
Carbapenem‐resistant Gram‐negative bacterial pathogens continue to threaten public health. Avibactam (AVI), a novel non‐β‐lactam β‐lactamase inhibitor, has been approved for use with ceftazidime (CAZ) mainly against carbapenem‐resistant Enterobacteriaceae. Therapeutic drug… Click to show full abstract
Carbapenem‐resistant Gram‐negative bacterial pathogens continue to threaten public health. Avibactam (AVI), a novel non‐β‐lactam β‐lactamase inhibitor, has been approved for use with ceftazidime (CAZ) mainly against carbapenem‐resistant Enterobacteriaceae. Therapeutic drug monitoring (TDM) is urgently needed to optimize dosage regimens to maximize efficacy, minimize toxicity, and delay the emergence of resistance. This study aims to develop and validate a rapid, simple, and economical LC–MS/MS method for simultaneous determination of CAZ/AVI in human plasma.
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!